<DOC>
	<DOCNO>NCT00545532</DOCNO>
	<brief_summary>This 2-arm study investigate safety tolerability oseltamivir treatment influenza immunocompromised participant characterize effect oseltamivir immunocompromised participant development resistant influenza virus . Eligible immunocompromised participant laboratory-confirmed influenza randomize receive either conventional dose ( 30 milligram [ mg ] -75mg twice daily orally [ po ] , depend age weight ) double dose ( 60mg-150mg twice daily po depend age weight ) Tamiflu 10 day . Nasal throat swab take , safety evaluation make , interval study . The anticipated time study medication 10 day anticipate time study 40 day .</brief_summary>
	<brief_title>A Study Oseltamivir ( Tamiflu ) Treatment Influenza Immunocompromised Participants .</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Oseltamivir</mesh_term>
	<criteria>Rapid diagnostic test , PCR , viral culture positive influenza 96 hour prior first dose Immunocompromised participant primary secondary immunodeficiency Symptoms suggestive influenzalike illness Use effective contraceptive , specify protocol ; woman childbearing potential pregnant breastfeeding Influenza vaccination live attenuate vaccine 2 week prior randomization Antiviral treatment influenza 2 week prior randomization Severe hepatic impairment Any current renal replacement therapy Any gastrointestinal disorder may interfere absorption oseltamivir Participation study investigational drug 4 week prior study start study end</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>